Literature DB >> 9462220

A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium.

.   

Abstract

BACKGROUND: The diagnosis of genetic haemochromatosis (GH) before iron overload has developed is difficult. However a convincing candidate gene for GH, HFE (previously HLA-H), has been described recently. AIMS: To determine the prevalence of the haemochromatosis associated HFE mutations C282Y and H63D in United Kingdom affected and control populations.
METHODS: The prevalence of the HFE C282Y and H63D mutations was determined by polymerase chain reaction amplification and restriction enzyme digestion in a cohort of 115 well characterised patients with GH and 101 controls from the United Kingdom.
RESULTS: One hundred and five of 115 (91%) patients with GH were homozygous for the C282Y mutation. Only one of 101 (1%) controls was homozygous for the C282Y mutation and this individual currently shows evidence of iron overload. Two of five patients who did not have either of the two described mutations of HFE had early onset iron overload (ages 16 and 24). One had a family history of cardiac failure and the second was subsequently hospitalised due to cardiac failure. These are the first phenotypic observations for patients without either C282Y or H63D mutation of HFE.
CONCLUSION: This simple genetic test promises to be a highly effective tool in the diagnosis of GH.

Entities:  

Mesh:

Year:  1997        PMID: 9462220      PMCID: PMC1891611          DOI: 10.1136/gut.41.6.841

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  [Letter: Idiopathic hemochromatosis associated with HL-A 3 tissular antigen].

Authors:  M Simon; Y Pawlotsky; M Bourel; R Fauchet; B Genetet
Journal:  Nouv Presse Med       Date:  1975-05-10

2.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

4.  Haemochromatosis and HLA-H.

Authors:  E C Jazwinska; L M Cullen; F Busfield; W R Pyper; S I Webb; L W Powell; C P Morris; T P Walsh
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

5.  Haemochromatosis and HLA-H.

Authors:  A M Jouanolle; G Gandon; P Jézéquel; M Blayau; M L Campion; J Yaouanq; J Mosser; P Fergelot; B Chauvel; P Bouric; G Carn; N Andrieux; I Gicquel; J Y Le Gall; V David
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

6.  Prevalence of haemochromatosis amongst asymptomatic Australians.

Authors:  B A Leggett; J W Halliday; N N Brown; S Bryant; L W Powell
Journal:  Br J Haematol       Date:  1990-04       Impact factor: 6.998

7.  Hemochromatosis: the impact of early diagnosis and therapy.

Authors:  L W Powell
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

8.  Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda.

Authors:  A G Roberts; S D Whatley; R R Morgan; M Worwood; G H Elder
Journal:  Lancet       Date:  1997-02-01       Impact factor: 79.321

9.  Serum ferritin, blood donation, iron stores and haemochromatosis.

Authors:  M Worwood; C Darke
Journal:  Transfus Med       Date:  1993-03       Impact factor: 2.019

10.  Mutation analysis in hereditary hemochromatosis.

Authors:  E Beutler; T Gelbart; C West; P Lee; M Adams; R Blackstone; P Pockros; M Kosty; C P Venditti; P D Phatak; N K Seese; K A Chorney; A E Ten Elshof; G S Gerhard; M Chorney
Journal:  Blood Cells Mol Dis       Date:  1996       Impact factor: 3.039

View more
  35 in total

Review 1.  Controversy in primary care: Should asymptomatic haemochromatosis be treated?

Authors:  C J Seamark; M Hutchinson
Journal:  BMJ       Date:  2000-05-13

Review 2.  Recent advances: hepatology.

Authors:  M McCarthy; M L Wilkinson
Journal:  BMJ       Date:  1999-05-08

3.  Hereditary haemochromatosis: never seen a case?

Authors:  J Emery; P Rose
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

4.  The case for strengthening education and training for general practice.

Authors:  T van Zwanenberg; M Pringle; S Smail; M Baker; S Field
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

5.  Hereditary haemochromatosis should be more widely known about.

Authors:  W Rosenberg; M Howell; P Roderick; D Eccles; I Day
Journal:  BMJ       Date:  1999-05-29

Review 6.  Molecular pathogenesis of iron overload.

Authors:  D Trinder; C Fox; G Vautier; J K Olynyk
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

7.  The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease.

Authors:  S Campbell; D K George; S D Robb; R Spooner; T A McDonagh; H J Dargie; P R Mills
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

8.  Heterozygosity for the haemochromatosis mutation HFE C282Y is not a risk factor for angina.

Authors:  G P Feeney; P A L Ashfield-Watt; M L Burr; F D J Dunstan; I F W McDowell; M Worwood
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 9.  Hepcidin: what every gastroenterologist should know.

Authors:  A P Walker; J Partridge; S K Srai; J S Dooley
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Fatty liver in H63D homozygotes with hyperferritinemia.

Authors:  Giada Sebastiani; Daniel F Wallace; Susan E Davies; Vasu Kulhalli; Ann P Walker; James S Dooley
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.